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Reliable methods for determining the localisation of mutant CFTR protein in native cells from CF individuals are necessary to allow the
degree of mislocalisation of any genotype to be defined and to assess the effect of therapeutic agents on CFTR trafficking. Here, we present
procedures for obtaining ciliated epithelial cells from CF patients by nasal brushing and a description of protocols for immunolocalisation of
CFTR. The protocols are a consensus, following comparison of some aspects of methods currently used in the authors’ laboratories.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; CFTR antibody; Immunolocalisation; Nasal brushing; Airways1. Introduction
Wild-type (wt) CFTR functions at the apical membrane
of epithelial cells, where it acts as a cyclic AMP-dependent
chloride (Cl) channel [1] and regulates other ion channels
[2] and protein secretion [3]. By far the most common
disease-causing mutation in CFTR is F508del, present on
70–80% of CF chromosomes worldwide. Cells transfected
with F508del-CFTR show reduced Cl channel activity
compared to wt since the protein is incorrectly processed,
retained within the endoplasmic reticulum (ER) and degrad-
ed to a greater extent than wt protein [4]. Native F508del/
F508del CF epithelial cells also have reduced Cl channel
activity at the cell membrane [5]. However, the degree of
mislocalisation of F508del-CFTR as demonstrated by1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.009
Abbreviations: Ab, antibody; ER, endoplasmic reticulum; PBS,
phosphate buffer saline; TCE (cells), tall columnar epithelial cells.
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E-mail address: dormer@cardiff.ac.uk (R.L. Dormer).immunostaining varies among different tissues and types
of preparation [6–11]. Nevertheless, the majority of immu-
nolocalisation studies have indicated that although some
F508del-CFTR was detected at the apical region, a substan-
tial amount was present within the cell.
It is very important to have reliable methods for
determining the localisation of mutant CFTR protein in
native cells from CF individuals. This allows: (a) the
degree of mislocalisation of any genotype to be defined;
(b) the effect of drugs, or other therapeutic strategies, on
CFTR trafficking to be assessed following in vitro or in
vivo administration. Although the degree of glycosylation
of CFTR has been used to determine whether a particular
mutation results in mislocalised CFTR [4], this technique is
only suitable for use in cell lines in which enough protein
is expressed for biochemical analysis (see Ref. [12]).
Studies in native, non-cultured, non-transfected cells
should be considered the ‘‘gold standard’’ for CF research
and for assessing the efficacy of new therapies. The study
of CFTR localisation and function in native airway epithe-
lial cells has been considerably advanced by the ability toed by Elsevier B.V. All rights reserved.
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procedure [13,14]. This technique has the advantage that
a range of subjects, in terms of age, sex, genotype and
disease conditions can be studied. Additionally, nasal
epithelium is considered to be representative of CF disease
in the lower airways [15]. The nasal brushing technique,
although far less invasive than those that sample bronchi or
lungs, gives some discomfort to the subject and studies
will usually require approval from local ethics committees.
It is important that harvesting cells from the brushes should
be rapid and cause minimal disturbance of the cells before
fixation for immunolocalisation. This will often have to be
balanced with the need to obtain enough cells for mean-
ingful testing of, for example, the effects of drugs on
CFTR location ex vivo. Our experience is that the tech-
nique, as described here, can yield highly polarised cells in
which quantitation of the percentage of cells with a defined
CFTR localisation can be determined. The technique thus
allows assessment of the effects of CFTR trafficking or
premature stop mutations, as well as those of drugs that
promote the trafficking of such mutant proteins to the
apical region [10,16].22. Towards a consensus protocol
The present article is based on the protocols described in
detail at the European Working Group on CFTR Expression
website [17]. The following sections will consider the three
steps of the technique, namely: (1) obtaining cells from
patients, (2) harvesting cells prior to experimentation and
(3) immunolocalisation of CFTR. For steps 2 and 3, we
have compared the distribution of cell types obtained and
the localisation of CFTR, in cells from CF patients and non-
CF controls by two published methods [9,10].
2.1. Obtaining cells from patients
For many researchers, this is dependent on collaboration
with clinical colleagues. Clinicians skilled in the art will
have their own methods but the protocol described provides
a detailed description.
2.1.1. Materials
Instruments that may be used alternatively to perform
nasal brushing: (1) interdental brushes: 2.5 mm diameter
for children, 3.0 mm diameter for adults (Paro-Isola,
Thalwil, Switzerland); (2) cytology brushes (Surgipath,
C-E brush #01970, Peterborough, UK)1; (3) rhino-probeR1 The experience in Cardiff is that these softer brushes are easier for
subjects to tolerate. This may be important if the technique is performed on
children or requires recruitment of volunteers, as opposed to taking
brushings as part of a clinical procedure to obtain cells for examination, e.g.
for ciliary dyskinesis.nasal curette (Arlington, IL, USA). Before use, brushes
should be washed thoroughly with 70% ethanol, rinse in
distilled water and sterilised under UV light overnight.
Collecting medium for living cells: Ham’s F12 or
DMEM/F12 culture media, containing (penicillin 100 U/
ml and streptomycin 100 Ag/ml) or phosphate-buffered
saline, PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4, pH 7.4).
2.1.2. Procedure
It is recommended that no anaesthesia should be used
when obtaining cells by nasal brushing.
1. Using an interdental brush: (a) Ask the subject to blow
the nose and thoroughly clean it and sit them in a chair
with the head against the wall in order to prevent head
withdrawal and tilt the subject’s head backward. (b)
Introduce a rhinoscope (closed) into a nostril, open it
slowly and inspect the inferior nasal meatus, using direct
light. Continue if the mucosa looks clean and healthy,
otherwise try with the other nostril. (c) Introduce the
brush and rub it against the posterior part of the inferior
nasal meatus (the medial and superior side of it), using
rotatory and linear movements. The subject will get tears
in the eye, but the discomfort will diminish rapidly.2 (d)
Take out the brush and put it in a tube containing 1 ml of
collecting medium or smear directly onto the surface of a
microscope slide (see below).3
2. Using a nasal curette: (a) The inferior nasal turbinate is
directly visualized by a lightened nasal speculum and the
curette is placed on the inferior medial surface (‘‘scoop
side up’’). (b) The probe is then pulled forward and
replaced three to four times to collect cells. (c) The
curette is smeared directly onto the surface of a
microscope slide.
2.2. Harvesting cells prior to experimentation
Cells can be harvested either by smearing directly onto
coated microscope slides (Snowcoat X-tra microslides,
Surgipath, Peterborough, UK) or by releasing cells from
the interdental brush into collecting medium using a dis-
posable pipette tip (described below). This has the advan-
tage of giving the best yield of cells and thereby a greater3 If transport between site of collection and laboratory is required, cells
collected in medium can be kept on ice for up to 8 h. It should however be
stressed that cells should be kept at 4 jC for as short a time as possible in
order to avoid any artefactual maturation of mutant CFTR.
The experience in Lisboa is that the subject is asked preferably to not
blow the nose or to blow very gently, to avoid any nasal tissue disturbance.
The brush is introduced into the nose without the help of a rhinoscope and
the tip of the inferior turbinate and the adjacent lateral nasal wall are
scraped using only linear movements.
Table 1
Comparison of CFTR distribution in nasal TCE cells fixed by two protocols
Genotype Method of fixation Percentage of cells with distribution described Number of cells counted
Within the cell Throughout the cell including
the apical region
Focused at the apical region
wt acetic acid/ethanol 22 33 45 100
formaldehyde/sucrose 24 31 45 61
F508del/F508del acetic acid/ethanol 66 26 8 38
formaldehyde/sucrose 66 27 8 52
Cells were obtained by nasal brushing from individuals with genotypes shown, as described [10]. Cells were smeared onto coated slides and fixed either with
acetic acid/ethanol as described or with formaldehyde/sucrose as in the consensus protocol. All cells were then processed for immunocytochemistry as
described [10] and cells categorised for CFTR distribution.
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CFTR localisation and function.4
2.2.1. Procedure
(a) Take a 200-Al disposable pipette tip and cut its
narrowest tip with a hot blade in order to obtain a hole
with a diameter almost equal to the brush’s diameter and
place it in a tube containing collecting medium. (b) Pass the
brush up and down three to four times through the opening
of the pipette tip, until the brush looks dry. (c) Cells can be
washed and resuspended in different media according to
needs by centrifugation (at 300 g for 5 min).
2.3. Immunocytochemical detection of CFTR
Cells spread onto microscope slides directly from the
brushing instrument or through harvesting by the procedure
described above (Section 2) can be subjected to different
immunocytochemistry protocols. Thus, before describing
the recommended procedure, the following sections show
comparisons of the localisation of CFTR in wt and CF cells
by two published methods [9,10]. The CFTR localisation
data in Tables 1 and 2 show direct comparisons, using the
MPCT-1 antibody (Ab) [10], carried out in the Cardiff
laboratory on a limited scale. An important advantage of
this technique is that the number of cells with a defined
CFTR localisation can be quantified. Only well-defined tall
columnar epithelial cells (TCE) are quantified and at least4 Cells smeared or centrifuged (see below) onto coated slides can be
stained either by May-Gru¨nwald’s method as described [9] or with
Toluidine Blue [10]. Data obtained in Cardiff laboratory using Toluidine
Blue showed that there is no alteration on the distribution of cell type
between the different harvesting procedures used (smearing onto slides or
removing cells by passage through a pipette tip): > 90% of the cells
observed were epithelial being approximately 70% tall columnar cells
(ciliated and non-ciliated) and 20% basal. Penque et al [9] described
detailed analysis of the cell types obtained with no difference among
populations from wt, F508del-heterozygotes or homozygous subjects. 80–
95% of cells obtained were epithelial; approximately 65–70% were tall
columnar cells, of which 60% were ciliated; approximately 20–25% were
basal cells. The data was similar to that of Bridges et al. [13] and Danel
et al. [14].100 cells per sample should be counted. This should be
routinely possible using the consensus procedure described
in Section 2; however, using the smear technique, fewer
cells are obtained and less cells may have to be counted, as
in Tables 1 and 2.
2.3.1. Comparison of fixation methods
The distribution of CFTR in ciliated epithelial cells from
a non-CF and a F508del/F508del CF individual was com-
pared following smearing onto coated slides and fixation in
either acetic acid/ethanol [10] or formaldehyde/sucrose [9].
Cells were categorised for CFTR distribution as previously
described [10]. As shown in Table 1, the method of fixation
had no effect on CFTR distribution in cells from either
individual. In non-CF cells, wt-CFTR was localised in the
apical region in 70–80% of the TCE cells, with differing
degrees of scatter throughout the cell. In F508del/F508del
CF cells, F508del-CFTR was predominantly restricted with-
in the cell5 (65–70% of cells) with approximately 10%
distinctly focused in the apical region. Recently, the Lisboa
group compared four different fixing solutions in nasal
epithelial cells from non-CF and F508del/F508del CF
individuals, namely: (a) acetone at  20 jC, formaldehyde
at 4 jC; (b) with and (c) without post-fixation with methanol
at  20 jC; and (d) acetic acid/ethanol [11]. Overall, it can
be concluded that none of the different methods of fixation
tested affected CFTR distribution.
2.3.2. Comparison of harvesting methods
The distribution of CFTR in ciliated epithelial cells
obtained at the same time from the same individual was
compared following either smearing onto coated slides and
fixation in acetic acid/ethanol [10] or using the harvesting
procedure described above (Section 2) and fixation in
formaldehyde/sucrose [9]. As shown in Table 2, essentially
the same pattern of CFTR localisation was observed in the
two populations. As described previously [10], the majority5 It should be noted that the Lisboa group do not routinely observe
intracellular staining that could be associated with the F508del trafficking
defect in TCE cells from F508del homozygous CF patients as is described
in Tables 1 and 2 and by other groups (see Refs [10,17]).
Table 2
Comparison of CFTR distribution in nasal TCE cells obtained by two protocols
Genotype Protocol Percentage of cells with distribution described Number of cells counted
Within the cell Throughout the cell including
the apical region
Focused at the apical membrane
wt Smear 22 33 45 100
PT 27 28 45 100
F508del/F508del Smear 66 26 8 38
PT 69 19 12 100
F508del/4016ins Smear 71 17 12 58
PT 91 6 3 100
Cells were obtained by nasal brushing from three individuals with the different genotypes shown, as described [10]. Cells from one brush were smeared onto
coated slides and fixed (‘smear method’); cells from a second brush were harvested as described in Section 2 above (pipette tip (PT) method). All cells were
then processed for immunocytochemistry as described [10] and cells categorised for CFTR distribution.
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whereas the majority of F508del/F508del cells showed
F508del-CFTR restricted within the cell. The same pattern
was seen in cells from a CF individual F508del/4016ins
expressing only one copy of F508del-CFTR as in F508del/
F508del cells (see also Ref. [10]). In addition, the action of
known F508del-CFTR trafficking drugs such as MPB-91Table 3
Outline of immunocytochemical detection protocols
Fixation and storage
Suspend cells in 1 ml of freshly prepared, ice-cold fixative
buffer (4% (v/v) formaldehyde + 3.7% (w/v) sucrose in PBS).
Incubate for 30 min on ice for fixation.
Centrifuge (300 g for 1 min), remove fixative buffer and wash
once with 1 ml of ice-cold PBS to remove fixative completely.
Re-suspend cells gently with P1000 micropipette (three times up
and down) between washes.
Finally, re-suspend cells again in cold PBS (0.3–1.0 ml).
Store at 4 jC until immunocytochemical analysis (maximum: 1 week)
Immunolocalisation
Centrifuge approx. 100 Al of cell suspension in a Cytospin for 5 min
at 2000 rpm for adherence to silane-coated slides.
Wash twice in PBS.
Permeabilize in 0.2% (v/v) Triton X-100 for 20 min.
Wash three times for 5 min each in PBS.
Block non-specific staining with 1% BSA (w/v) for 45 min.
Incubate with primary Ab (diluted in 1% BSA (w/v)) overnight at 4 jC.
Wash three times for 10 min each in PBS.
Incubate with secondary Ab (diluted in 0.5% BSA (w/v)) for 45 min.
Wash three times for 10min each in PBS.
Mount slides with coverslips in Vectashield containing the nuclear
stain, DAPI[10] was also observed in cells isolated by either procedure
(data not shown).
2.3.3. Comparison of antibodies
The distribution of CFTR in cells obtained from non-CF
individuals or F508del-homozygous CF patients, either as
described by the consensus protocol (Section 2 and Table 3)Allow cells to adhere to slides coated with ‘Cell-tak’ (Beckton Dickinson
Biosciences, Oxford, UK).
Wash slides with PBS and stored in a moist chamber at 4 jC
(maximum: 1 week)
Incubate slides in PBS/1% Tween-20 for 5 min.
Block non-specific staining with goat serum (1:20 in PBS/1% Tween-20)
for 20 min.
Incubate with primary Ab (diluted in PBS+ 0.1% Tween-20/0.1% BSA)
overnight at 4 jC.
Wash three times for 10 min each in PBS/1% Tween-20,
Incubate with secondary antibody (diluted in PBS+ 0.1% Tween-20/0.1%
BSA) for 30 min.
Wash three times for 10 min each in PBS/1% Tween-20
Add the red nuclear stain propidium iodide (Sigma, St. Louis, MO, USA)
to cells for 5 min.
Wash three times for 5 min each in PBS/1% Tween-20.
Mount slides with coverslips using Fluorosave (Calbiochem, Nottingham,
UK) to prevent excessive bleaching of fluorescence.
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the MPCT-1 Ab. There was no difference in the percentage
of wt or F508del/F508del cells showing CFTR in the apical
region, irrespective of method of isolation used. A detailed
comparison of the application of a wider range of CFTR
Abs in immunolocalisation has recently been published
[11,18] and is also summarised in an accompanying article
in this Supplement [19].
2.3.4. Procedure
In view of the comparisons described above, the proce-
dure shown in Table 3 offers two alternative protocols that
give similar results on cells harvested from brushes as
described in Section 2. Unless otherwise stated, all proce-
dures are carried out at room temperature and solutions
made up in PBS.3. Discussion
The technique described above for immunolocalisation
of CFTR in freshly isolated native airway epithelial cells
from CF patients allows quantitation of the percentage of
cells with a defined CFTR location. It is recommended that
at least 100 columnar ciliated cells should be examined to
give meaningful results. The consensus protocol gives
similar results to other published methods that have used
different methods of isolating and fixing nasal epithelial
cells for immunolocalisation.
It is important that the effects of mislocalisation of
mutant CFTR and its correction by drug or other therapies
on CFTR function, should also be assessed in parallel. For
this purpose, the Cl transport function of CFTR can be
measured by imaging of single cells containing fluorescent
Cl indicators. A protocol for this technique is presented
in an accompanying article in this Supplement [20]. CFTR
function can also be measured in vivo by nasal PD, a
technique described in detail elsewhere [21]. Although
CFTR function is normally measured in fewer cells from
a given population than its location, assessment of the
heterogeneity of cellular responses in cells with the same
CF genotype is an important factor in determining the
relationship between genotype and phenotype in this
disease.
In summary, it can be concluded that: (1) a minority (10–
20%) of native F508del/F508del CF airways cells show
CFTR in the apical membrane. (2) Most F508del/F508del
CF cells show mislocalised CFTR, which is retained within
the cell.
The demonstration that the majority of F508del-CFTR is
mislocalised emphasises that moving F508del-CFTR to the
apical membrane is necessary for developing a drug treat-
ment targeted at CFTR rescue. The consensus protocol
described can be used to test for relocation of F508del-CFTR
to the apical region caused by drugs aimed at pharmacolog-
ical correction of the basic CFTR trafficking defect.Acknowledgements
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